Neurological disorders Archives

More News! 14 Sep 2017

New Dutch Spin Out will Treat Stroke with RNA Therapy

ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […]

September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

brain organoids tissue engineering austria

News and Trends 2 Jun 2017

Austrian Researchers build an improved Mini-Brain to support Psychiatry

Researchers from Austria and the UK have made new advances in engineering brain-like structures. These lab-grown organoids mimic important functions of the real thing and could help improve understanding of mental illness and test new therapies. The Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna is a pioneer of brain […]

June 2, 2017 - 2 minutesmins - By Denise Neves Gameiro

cannabidiol cannabis epilepsy davet syndrome epidiolex gw pharmaceuticals cbd

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […]

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

News and Trends 18 May 2017

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […]

May 12, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

Mission Therapeutics Parkinsons research grant

News and Trends 11 Apr 2017

New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK

Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day today, Mission Therapeutics has announced it has been awarded a research grant from the Michael J. Fox Foundation in the US. Named after its founder, the star of […]

April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 10 Apr 2017

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can at the problem of Alzheimer’s Disease without any success to show for its efforts. Now the sixth leading cause of death across all age groups, […]

April 10, 2017 - 7 minutesmins - By Evelyn Warner

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer’s. Roche just announced plans to start two new Phase III studies in Alzheimer’s with its antibody candidate gantenerumab, initially developed by the German biotech giant MorphoSys. The trials are expected to begin later this year, but Roche […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

AlzProtect crowdfunding neurodegenerative disease

News and Trends 15 Feb 2017

French Biotech bids for Crowdfunding in Neurodegenerative Disease

AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease. To support the progression of its lead candidate, AZP2006, the company has decided to turn to an unusual source of money that seems to be […]

February 15, 2017 - 2 minutesmins - By External Contributor

News and Trends 13 Feb 2017

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […]

February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us